Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Navidea Biopharmaceuticals, Inc. < Previous 1 2 Next > Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting October 05, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders September 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting September 15, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma September 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees September 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update August 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering August 25, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering August 18, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results August 15, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering August 04, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia August 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering August 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV July 25, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding July 05, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting May 24, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting May 23, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results May 12, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update May 05, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis April 20, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets April 20, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis April 19, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India April 18, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series April 12, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American April 12, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs April 07, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results March 23, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results March 23, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update March 16, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma February 07, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American February 03, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.